Blockchain Registration Transaction Record

Soligenix's HyBryte(TM) Shows Promise in CTCL Treatment

Soligenix updates on HyBryte(TM) for CTCL treatment, showing 75% disease severity reduction in early study. Phase 3 results expected by 2026.

This news is significant because it highlights a potential breakthrough in the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often debilitating form of non-Hodgkin's lymphoma. The promising interim results from the University of Pennsylvania study suggest that HyBryte(TM) could offer a new, effective treatment option for patients, improving their quality of life and potentially changing the standard of care for CTCL. The anticipation of phase 3 trial results in 2026 also marks an important milestone in the development of this therapy, offering hope to patients and their families.